Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15147193 | 0.88 | KMT2A (0.57) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31490563 | 0.85 | KMT2A (0.59) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL20193277 | 0.85 | KMT2A (0.59) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL20193301 | 0.85 | KMT2A (0.59) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL16790448 | 0.83 | KMT2A (0.63) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL16790447 | 0.82 | KMT2A (0.62) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31490569 | 0.82 | KMT2A (0.51) | KMT2AEPHX2CASP3 | |
| SCHEMBL14008330 | 0.82 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31652641 | 0.81 | KMT2A (0.75) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL15147183 | 0.80 | KMT2A (0.49) | KMT2AEPHX2CASP3CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10667935-B2 | Methods for making conjugates from disulfide-containing proteins | NOVARTIS AG (CH) | 2020-06-02 | — | — | US | disclosed |
| US-20190038444-A1 | METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038444-A1 | METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS | PDIA6, PTMS, PDIA3 | KMT2A 1024/4885EPHX2 2024/4885FABP7 281/4885 |
| US-10667935-B2 | Methods for making conjugates from disulfide-containing proteins | PDIA6, PTMS, PDIA3 | KMT2A 1024/4885EPHX2 2024/4885FABP7 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.